Marshall Wace
CHNG

Marshall Wace’s Change Healthcare Inc. Common Stock CHNG Stock Holding History

Marshall Wace’s Portfolio CHNG Stock Details CHNG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,372,838
Closed -$37.7M – 3899
2022
Q3 		$37.7M Buy
1,372,838
+890,579
+185% +$22.1M 0.08% 268
2022
Q2 		$11.1M Buy
482,259
+101,721
+27% +$2.38M 0.02% 791
2022
Q1 		$8.3M Sell
380,538
-77,950
-17% -$1.62M 0.02% 1011
2021
Q4 		$9.8M Buy
458,488
+32,518
+8% +$682K 0.02% 880
2021
Q3 		$8.92M Sell
425,970
-322,346
-43% -$7.03M 0.04% 623
2021
Q2 		$17.2M Sell
748,316
-182,974
-20% -$4.21M 0.08% 279
2021
Q1 		$20.6M Buy
931,290
+636,823
+216% +$14.7M 0.09% 209
2020
Q4 		$5.49M Sell
294,467
-224,434
-43% -$3.69M 0.03% 537
2020
Q3 		$7.53M Buy
518,901
+329,881
+175% +$4.19M 0.05% 384
2020
Q2 		$2.12M Buy
189,020
+144,585
+325% +$1.62M 0.01% 767
2020
Q1 		$444K Buy
+44,435
New +$621K ﹤0.01% 1003

Other funds holding CHNG

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Marshall Wace's CHNG Position: Q4 2022 in Review

Marshall Wace sold out of Change Healthcare Inc. Common Stock (CHNG) in Q4 2022, closing a stake of 1,372,838 shares — an estimated $37.7M sold.

Marshall Wace first reported a position in CHNG in Q1 2020 and held it in 11 quarters. The position peaked at $37.7M in Q3 2022. 1 fund tracked by Wall St. Rank holds CHNG as of Q4 2022.

  • Marshall Wace reported no remaining Change Healthcare Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Marshall Wace sold 1,372,838 Change Healthcare Inc. Common Stock shares in Q4 2022, an estimated $37.7M.
  • Marshall Wace first reported a position in Change Healthcare Inc. Common Stock in Q1 2020 and held it in 11 quarters.
  • Marshall Wace's Change Healthcare Inc. Common Stock position peaked at $37.7M in Q3 2022.
  • 1 fund tracked by Wall St. Rank held Change Healthcare Inc. Common Stock as of Q4 2022.

Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.